IndraLab

Statements

Mutated EGFR-vIII increases the amount of USP11. 4 / 4
| 4
reach
"CONCLUSIONS: EGFR-vIII mutation downregulates H2AZK4/7AC and H3K27AC, inhibiting USP11 expression though the PI3K/AKT-HDAC1/2 axis."
31993801
reach
"FK228 could enhance anti-tumour activity by upregulating expression of the tumour suppressor USP11 in GBM cells.Conclusions: EGFR-vIII mutation downregulates H2AZK4/7AC and H3K27AC, inhibiting USP11 expression though the PI3K/AKT-HDAC1/2 axis."
31993801
reach
"EGFR-vIII mutation can downregulate H2AZK4/7AC and H3K27AC, inhibiting USP11 expression though the PI3K/AKT-HDAC1/2 axis."
31993801
reach
"We demonstrated that the EGFR-vIII mutation downregulated H2AZK4/7AC and H3K27AC, inhibiting USP11 expression though the PI3K/AKT-HDAC1/2 axis."
31993801